ACUTE ATORVASTATIN RECAPTURE THERAPY IN CORONARY ARTERY BYPASS GRAFTING

QR Code

ACUTE ATORVASTATIN RECAPTURE THERAPY IN CORONARY ARTERY BYPASS GRAFTING

Aim. To assess the safety of the application of high-dose atorvastatin and its effect on metabolic parameters, such as the total level of nitric oxide and homocysteine in the blood plasma in patients with ischemic heart disease during a coronary artery bypass surgery (CABG).Material and methods. The...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. V. Panov, M. L. Gordeev, A. A. Zhloba, T. F. Subbotina, I. V. Suhova, M. I. Buthashvili, I. T. Abesadze, M. Z. Alugishvili, N. L. Lohovinina, K. V. Korzhenevskaya, M. V. Solovyova, L. V. Mihaylova, E. S. Alekseevskaya
Format:	Article
Language:	English
Published:	Столичная издательская компания 2017-07-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	ischemic heart disease coronary artery bypass grafts surgery acute statin recapture therapy atorvastatin
Online Access:	https://www.rpcardio.online/jour/article/view/1476
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ATORVASTATIN IN ACUTE AND CHRONIC KINDS OF ISCHEMIC HEART DISEASE
by: V. E. Oleynikov, et al.
Published: (2015-11-01)

ATORVASTATIN — 20 YEARS IN THE STRUGGLE FOR LIFE
by: N. G. Gogolashvili
Published: (2018-03-01)

Atorvastatin: evidence base 15 years later
by: A. V. Susekov, et al.
Published: (2011-06-01)

Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
by: Sh. A. Mostafa, et al.
Published: (2018-11-01)

Aggressive statin therapy in acute coronary syndrome: therapeutic potential of atorvastatin in the daily dose of 80 mg
by: A. N. Britov
Published: (2009-12-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

Nephroprotective effect of atorvastatin at a dose of 80 mg in patients with ST-segment elevation myocardial infarction with an invasive treatment strategy
by: A. D. Gavrilko, et al.
Published: (2023-11-01)

Choosing lipid lowering statin in risk strategy of cardiovascular event prevention
by: A. Ya. Yvleva, et al.
Published: (2007-02-01)

LIPRIMAR®. FIFTEEN YEARS OF EVIDENCE
by: A. V. Susekov, et al.
Published: (2016-01-01)

STATINS IN PREVENTION OF ISCHEMIC STROKE
by: A. V. Susekov, et al.
Published: (2015-09-01)

Statin therapy in atherosclerosis prevention: modern strategy and tactics
by: M. G. Bubnova
Published: (2009-06-01)

Statins in acute coronary syndrome
by: O. M. Drapkina
Published: (2009-10-01)

COMPARATIVE EFFICACY OF THE STATINS IN PREVENTING AND TREATING OF THE CORONARY HEART DISEASE
by: S. V. Shalaev, et al.
Published: (2016-01-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

Analysis of the binary mixtures of amlodipine and atorvastatin by chemometric-spectophotometric method
by: Hayrettin Bulum, et al.
Published: (2025-06-01)

EFFICIENCY AND SAFETY ASSESSMENT OF GENERIC ATORVASTATINE IN PATIENTS WITH HYPERLIPIDEMIA
by: J. E. Semyonova, et al.
Published: (2015-12-01)

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

Dose-dependent effects of atorvastatin in the hospitalisation period of myocardial infarction
by: O. L. Barbarash, et al.
Published: (2013-06-01)

THE ROLE OF LIPOTROPIC THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE BEFORE AND AFTER CORONARY REVASCULARIZATION
by: R. N. Adzhiev, et al.
Published: (2015-09-01)

Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension
by: N. B. Amirov, et al.
Published: (1970-01-01)

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES
by: A. N. Meshkov
Published: (2016-01-01)

A case of rhabdomyolysis after atorvastatin therapy of a liver transplant recipient receiving immunosuppressive therapy with cyclosporine
by: A. V. Shabunin, et al.
Published: (2021-06-01)

Biochemical, structural and clinical analysis of statins’ pleiotropic effects
by: A. N. Britov, et al.
Published: (2009-10-01)

Effect of spatial overdispersion on confidence intervals for population density estimated by spatial capture–recapture
by: Efford, Murray G., et al.
Published: (2025-07-01)

USE OF DISSOLUTION TEST FOR EVALUATION OF PHARMACEUTICAL EQUIVALENCE OF ATORVASTATIN GENERICS
by: O. V. Druzhininskaya, et al.
Published: (2019-01-01)

Statin choice for lipid6lowering therapy: clinical pharmacology and evidence-based medicine position
by: S. V. Nedogoda
Published: (2008-02-01)

EFFECTS OF AN EIGHT-WEEK ATORVASTATIN TREATMENT ON SPONTANEOUS CYTOKINE PRODUCTION BY THE BLOOD MONONUCLEAR LEUKOCYTES IN METABOLIC SYNDROME
by: I. D. Bespalovа, et al.
Published: (2014-11-01)

Atorvastain effectiveness in patients with heart failure, preserved systolic function, and paroxysmal atrial fibrillation
by: E. S. Kozlova, et al.
Published: (2009-12-01)

Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin)
by: R. G. Oganov, et al.
Published: (2006-12-01)

ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE
by: M. V. Solodun, et al.
Published: (2015-09-01)

Possibilities of atorvastatin loading dose using for the prevention of perioperative myocardial damage in patients with stable coronary artery disease
by: A. S. Ragozina, et al.
Published: (2019-11-01)

ANTIATHEROGENIC AND PLEIOTROPIC ACTIVITY OF VARIOUS DOSES OF ATORVASTATIN IN PATIENTS WITH ISCHEMIC STROKE
by: M. G. Bubnova, et al.
Published: (2013-08-01)

THE USE OF ATORVASTATIN FOR THE PREVENTION OF RECURRENT ATRIAL FIBRILLATION AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: S. N. Tereshchenko, et al.
Published: (2016-01-01)

Features and main problems of treating patients with high and very high cardiovascular risk with statins in real clinical practice (according to the data of the “PRIORITET” research)
by: S. Yu. Martsevich, et al.
Published: (2018-12-01)

Anti-inflammatory effects of low- and high-dose atorvastatin therapy in patients with coronary heart disease and rheumatoid arthritis
by: V. S. Tutunov, et al.
Published: (2008-10-01)

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness
by: A. V. Susekov, et al.
Published: (2007-06-01)

RECENT ADVANCES IN THE APPLICATION OF HIGH DOSES OF ATORVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE
by: M. V. Ezhov
Published: (2016-01-01)

Atorvastatin therapy and antioxidant status correction in patients with metabolic syndrome
by: N. S. Yubitskaya, et al.
Published: (2013-06-01)

Adherence to Statins Therapy of High and Very High Cardiovascular Risk Patients in Real Clinical Practice: Diagnostics and Possible Ways to Solve the Problem (According to the PRIORITY Observational Study)
by: S. Yu. Martsevich, et al.
Published: (2019-01-01)

THE INFLUENCE OF ATORVASTATIN AND ROSUVASTATIN IN ATHEROSCLEROSIS ON THE PARAMETERS OF CELLULAR IMMUNITY AND IN VITRO LEUCOCYTE ACTIVATION
by: A. Yu. Filatova, et al.
Published: (2018-09-01)